May 27, 2020 Synthetic Biologics Enters into Exclusive Option to License Intellectual Property for Use of SYN-020 to Treat and Prevent Age-Related Metabolic and Inflammatory Diseases
May 5, 2020 Synthetic Biologics Reports 2020 First Quarter Operational Highlights and Financial Results
April 28, 2020 Synthetic Biologics to Report 2020 First Quarter Operational Highlights and Financial Results on May 5, 2020
February 20, 2020 Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results
February 13, 2020 Synthetic Biologics to Report 2019 Year End Operational Highlights and Financial Results on February 20, 2020
January 7, 2020 Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients
November 27, 2019 Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan
November 4, 2019 Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results
